1. Prasugrel inhibits platelet-enhanced pro-inflammatory CD4+ T cell responses in humans. Issue 1 (March 2015) Authors: Johnston, L.R.; La Flamme, A.C.; Larsen, P.D.; Harding, S.A. Journal: Atherosclerosis Issue: Volume 239:Issue 1(2015) Page Start: 283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prasugrel inhibits platelet-enhanced pro-inflammatory CD4+ T cell responses in humans. Issue 1 (March 2015) Authors: Johnston, L.R.; La Flamme, A.C.; Larsen, P.D.; Harding, S.A. Journal: Atherosclerosis Issue: Volume 239:Issue 1(2015) Page Start: 283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers. (December 2016) Authors: Blake, J.; Kolakowski, G.R.; Tuch, B.; Ebata, K.; Brandhuber, B.; Winski, S.; Bouhana, K.; Nanda, N.; Wu, W.I.; Parker, A.; Hamor, R.; Larsen, P.D.; Sullivan, F.; DeWolf, W.; Neitzel, N.; Wollenberg, L.; Andrews, S.; Rothenberg, S.M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗